Insert Therapeutics is focused on designing, developing and commercializing delivery-enhanced therapeutics using our patented class of polymeric delivery systems, which we have called our " Cyclosert™ " family of linear cyclodextrin-containing polymers. We are developing proprietary Cyclosert™ -drug conjugates using off-patent compounds that have documented efficacy, but which also have known issues relating to their solubility, stability, undesirable side effects or poor pharmacokinetics that we can improve significantly with Cyclosert™ .
Insert was founded in February 2000 and is headquartered in Pasadena, California. Insert is a majority-owned subsidiary of Arrowhead Research Corporation.
129 N. Hill Ave. , Suite 104